Metraipolis › archive › dc_b9a76ca74ea2

The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2 — Europe PMC PMID:41258893

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41258893
DOI
10.7554/elife.103484
License (as archived)
CC0-1.0
Archived
2026-10-06T08:50:04.233Z
SHA-256 of the archived text
84f06fc2d637f97c58f23c29c77cbb0a51a8347efd943fc21216d9e45739e258
Stable URL of this page
https://metraipolis.com/documento/dc_b9a76ca74ea2

How to cite

The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2 — Europe PMC PMID:41258893 — Europe PMC (en), https://europepmc.org/article/MED/41258893 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_b9a76ca74ea2 (Metraipolis archive dc_b9a76ca74ea2, sha256 84f06fc2d637f97c58f23c29c77cbb0a51a8347efd943fc21216d9e45739e258)
BibTeX
@misc{dcb9a76ca74ea2,
  title = {The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2 — Europe PMC PMID:41258893},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41258893},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_b9a76ca74ea2; sha256 84f06fc2d637f97c58f23c29c77cbb0a51a8347efd943fc21216d9e45739e258},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/41258893. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to pose a threat to public health. Current therapeutics remain limited to direct-acting antivirals that lack distinct mechanisms of action and are already showing signs of viral resistance. The virus encodes an ADP-ribosylhydrolase macrodomain (Mac1) that plays an important role in the coronaviral life cycle by suppressing host innate immune responses. Genetic inactivation of Mac1 abrogates viral replication in vivo by potentiating host innate immune responses. However, it is unknown whether this can be achieved by pharmacologic inhibition and can therefore be exploited therapeutically. Here, we report a potent and selective lead small molecule, AVI-4206, that is effective in an in vivo model of SARS-CoV-2 infection. Standard cellular models indicate that AVI-4206 has high target engagement and can weakly inhibit viral replication in a gamma interferon- and Mac1 catalytic activity-dependent manner. However, a stronger antiviral effect for AVI-4206 is observed in human airway organoids and peripheral blood monocyte-derived macrophages. In an animal model of severe SARS-CoV-2 infection, AVI-4206 reduces viral replication, potentiates innate immune responses, and leads to a survival benefit. Our results provide pharmacological proof of concept that Mac1 is a valid therapeutic target via a novel immune-restoring mechanism that could potentially synergize with existing therapies targeting distinct, essential aspects of the coronaviral life cycle. This approach could be more widely used to target other viral macrodomains to develop antiviral therapeutics beyond COVID-19.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: eLife, 2025 (prima pubblicazione 2025-11-19).
Identificativi: PMID 41258893 · PMCID PMC12629595 · DOI 10.7554/elife.103484.
Parole chiave degli autori: Viruses; Mouse; Microbiology; Infectious disease; Structure-Based Drug Design; X-ray crystallography; Coronavirus; Macrodomain; Covid.
Descrittori MeSH principali: N-Glycosyl Hydrolases; Antiviral Agents; SARS-CoV-2; COVID-19 Drug Treatment.
Pagina: https://europepmc.org/article/MED/41258893 — https://doi.org/10.7554/elife.103484. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-06T08:20:26.577Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.